largazole and Corneal-Neovascularization

Histone deacetylases (HDACs) regulate gene transcription by modifying the acetylation level of histone and nonhistone proteins. In this study, we examined the effect of largazole, an inhibitor of class I HDACs, on inflammatory corneal angiogenesis. In a mouse model of alkali-induced corneal neovascularization (CNV), topical application of largazole to the injured corneas attenuated CNV. In addition, in vivo treatment with largazole down-regulated the expression of the pro-angiogenic factors VEGF, b-FGF, TGFβ1 and EGF but up-regulated the expression of the anti-angiogenic factors Thrombospondin-1 (Tsp-1), Tsp-2 and ADAMTS-1 in the injured corneas. Furthermore, largazole inhibited the expression of pro-angiogenic factors, migration, proliferation and tube formation by human microvascular endothelial cells (HEMC-1) in vitro. These data indicate that largazole has therapeutic potential for angiogenesis-associated diseases.

Topics: ADAM Proteins; Animals; Anti-Inflammatory Agents; Cell Line; Cell Movement; Cell Proliferation; Corneal Neovascularization; Depsipeptides; Endothelial Cells; Epidermal Growth Factor; Female; Fibroblast Growth Factors; Histone Deacetylase Inhibitors; Humans; Mice, Inbred BALB C; RNA, Messenger; Thiazoles; Thrombospondin 1; Thrombospondins; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A